In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Balaglitazone is a partial agonist of peroxisome proliferator-activated receptor (PPAR) γ .
PPAR plays important roles in the regulation of insulin, triglycerides and lipid metabolism. It is an attractive target for the therapy of Type II Diabetes. Balaglitazone is a partial agonist of PPARγ. The maximum inhibition of PPARγ activity by balaglitazone is 52%. Thus balaglitazone is supposed to have decreased side effects. It has showed potent effects on lowering blood glucose in various animal models [1 and 2].
In a cell-based assay using HEK293 cells transfected with fused PPARγ, treatment of balaglitazone showed sigmoid activation with an EC50 value of 1.35μM. When combined with rosiglitazone, balaglitazone at increased concentrations resulted in the reduction of rosiglitazone’s activity to the level of balaglitazone alone at concentration of 100 nM .
In adult male diabetic mice, the oral administration of balaglitazone at increased doses showed more potent and efficacious at lowering glucose levels than rosiglitazone. Balaglitazone also caused reduction of bodyfluid accumulation andfat accumulation without heart enlargement, indicating that it had a better safety profile on the cardiovascular system. Besides that, balaglitazone treatment lasted for 21 days exerted no significant impact on the volumes of blood or plasma. Moreover, balaglitazone was found to have no effect on bone formation at concentrations of up to 10 mg/kg indicating that it was only a partial agonist and led no loss of bone [1 and 2].
 Agrawal R, Jain P, Dikshit SN. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini Rev Med Chem. 2012 Feb;12(2):87-97.
 Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):340-5.
 Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Synonyms||DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344|
|Solubility||≥15.45 mg/mL in DMSO, ≥2.18 mg/mL in EtOH with ultrasonic and warming,insoluble in H2O|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|
|Description||Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.|